“Singapore has geographical and policy advantages in Southeast Asia, the Middle East, and broader emerging markets. In recent years, it has become a global hub for capital and innovation, thanks to its excellent financial system, open and inclusive policy environment, and rapidly developing pharmaceutical industry.”
China Medical System Holdings (CMS), a Hong Kong-listed pharmaceutical company, is joining a growing list of overseas companies with a secondary listing on the Singapore Exchange (SGX) as it accelerates its internationalisation push and shifts its focus towards Southeast Asia and the Middle East.
“CMS has chosen to conduct the secondary listing in Singapore mainly based on its strategic layout of ‘industry internationalisation’ and market expansion considerations,” says a spokesperson from the group in an e-mail interview with The Edge Singapore.
